DBS Revenue Growth
11%
+330bps vs IPM
Domestic branded business outperformed the Indian Pharma Market by 330 bps.
ERISLIFESCIENCES
Healthcare
12 Aug 2025
Eris Lifesciences Ltd — Q3 FY26
Eris Lifesciences reported Q1 FY26 consolidated revenue of ₹773 crore (+7.4% YoY) and PAT of ₹125 crore (+41% YoY), driven by strong domestic branded business (DBS) growth of 11% and margin expansion.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Eris Lifesciences reported Q1 FY26 consolidated revenue of ₹773 crore (+7.4% YoY) and PAT of ₹125 crore (+41% YoY), driven by strong domestic branded business (DBS) growth of 11% and margin expansion. DBS EBITDA margin improved to 37.2% (+155 bps YoY), while the BioOn segment reached 30% EBITDA margin (vs 19% at acquisition). The company reaffirmed consolidated guidance despite a planned ramp-down of trade generics (₹3 crore revenue vs ₹13 crore last year). Key growth drivers include insulin cartridge manufacturing commencement at Bopal (Q4), GLP-1 pipeline progress (synthetic semaglutide validation, recombinant candidate entering Phase 1 in Q4), and a confirmed CDMO pipeline of ₹100 crore+ for international business. Risks include persistent insulin drug product shortages (20% gap) and capacity constraints in injectables for 1.5-2 years.
Key Numbers
BioOn EBITDA Margin
30%
+1100bps vs acquisition
BioOn segment margin improved from 19% at acquisition to 30% in Q1.
Cash EPS
₹12
+41% YoY
Cash EPS grew 41% year-on-year, driven by PAT growth and lower depreciation.
CDMO Contracted Revenue
₹100 crore+
New
Confirmed CDMO contracts worth over ₹100 crore annual revenue in various execution stages.
Management Guidance
Consolidated revenue growth 15-21% for FY26
Management reaffirmed the earlier guidance despite Q1 growth of 7.4%, citing ramp-down of trade generics as a temporary drag.
Management guidance revenueNet debt target of ₹1,800 crore by FY26 end
Net debt stood at ₹2,300 crore in Q1; management reaffirmed reduction to ₹1,800 crore by year-end, implying net debt/EBITDA of ~1.5x.
Management guidance otherInsulin cartridge production to commence in Q4 FY26
Manufacturing of insulin cartridges at Bopal expected to start in Q4, with market opportunity from Novo Nordisk's exit accruing from Nov-Dec 2025.
Management guidance expansionInternational business to reach ₹1,000 crore by FY28-29
Includes CDMO, RO business, OSD exports, and B2C; CDMO commercialization expected from FY27 with ₹100 crore+ confirmed contracts.
Management guidance growthKey Risks
Persistent insulin drug product shortages
DP shortages continue, causing a 20% gap in supply; management noted a ₹10 crore revenue hit in Q1 and a strategic stockpile increased working capital by ₹73 crore.
high · management_commentaryCapacity constraints in injectables for 1.5-2 years
Management acknowledged capacity constraints in a couple of lines, limiting volume growth until new unit is commissioned, which may take 1.5-2 years.
medium · analyst_questionGLP-1 market formation delay or competition
Liraglutide (LRA) ramp-up slower than expected due to stiff competition and delayed obesity approval for generic exenatide; management lowered near-term expectations.
medium · analyst_questionTrade generics ramp-down impact on revenue
Trade generics revenue fell from ₹13 crore to ₹3 crore YoY; full-year impact could be ~₹40 crore revenue loss, though it was never profitable.
low · data_observationNotable Quotes
We retain our position that we expect to be among the first launches in India post LOE.
The only problem which we see in the export business injectable is a little bit of a capacity problem and this would remain for at least one and a half years.
Our DBF aggregate margins are at 37%. So I would say that is the kind of aspiration we would have at the very least.
Frequently Asked Questions
What was Eris Lifesciences's revenue in Q3 FY26?
Eris Lifesciences reported revenue of ₹807 Cr in Q3 FY26, representing a +7.4% change compared to the same quarter last year.
What guidance did Eris Lifesciences management give for FY27?
Consolidated revenue growth 15-21% for FY26: Management reaffirmed the earlier guidance despite Q1 growth of 7.4%, citing ramp-down of trade generics as a temporary drag. Net debt target of ₹1,800 crore by FY26 end: Net debt stood at ₹2,300 crore in Q1; management reaffirmed reduction to ₹1,800 crore by year-end, implying net debt/EBITDA of ~1.5x. Insulin cartridge production to commence in Q4 FY26: Manufacturing of insulin cartridges at Bopal expected to start in Q4, with market opportunity from Novo Nordisk's exit accruing from Nov-Dec 2025. International business to reach ₹1,000 crore by FY28-29: Includes CDMO, RO business, OSD exports, and B2C; CDMO commercialization expected from FY27 with ₹100 crore+ confirmed contracts.
What are the key risks for Eris Lifesciences in FY27?
Key risks include Persistent insulin drug product shortages — DP shortages continue, causing a 20% gap in supply; management noted a ₹10 crore revenue hit in Q1 and a strategic stockpile increased working capital by ₹73 crore.; Capacity constraints in injectables for 1.5-2 years — Management acknowledged capacity constraints in a couple of lines, limiting volume growth until new unit is commissioned, which may take 1.5-2 years.; GLP-1 market formation delay or competition — Liraglutide (LRA) ramp-up slower than expected due to stiff competition and delayed obesity approval for generic exenatide; management lowered near-term expectations.; Trade generics ramp-down impact on revenue — Trade generics revenue fell from ₹13 crore to ₹3 crore YoY; full-year impact could be ~₹40 crore revenue loss, though it was never profitable..
Did Eris Lifesciences meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Eris Lifesciences Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.